PharmiWeb.com - Global Pharma News & Resources
31-Aug-2021

Immutep announces Chinese patent grant for LAG-3 antagonist antibody LAG525

Immutep announces Chinese patent grant for LAG-3 antagonist antibody LAG525

Sydney, Australia,  August 27, 2021 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), is pleased to announce the grant of patent no. ZL201580013695.X entitled “Antibody molecules to LAG-3 and uses thereof” by the Chinese Patent Office.

This new Chinese patent follows the grant of the corresponding Australian, United States, European, and Japanese patents announced in 2018 through 2020.

In particular, the claims of the patent are directed to LAG525, pharmaceutical compositions comprising LAG525, nucleic acid molecules that code for the LAG525 antibody, an expression vector or host cell that comprises the nucleic acid molecules, and to the use of LAG525 in the manufacture of preparation for the treatment of cancer or infectious disease.

LAG525 (INN: leramilimab) is a humanised form of Immutep’s IMP701 antibody which is out-licensed to Novartis AG.

The patent is co-owned by Novartis AG and Immutep S.A.S. and will expire on 13 March 2035.

About IMP701 and LAG525
IMP701 is a therapeutic antagonist antibody originally developed by Immutep S.A. (now Immutep S.A.S.) to target LAG-3. This antibody plays a role in controlling the signalling pathways in both effector T cells and regulatory T cells (Treg). The antibody works by activating effector T cells by blocking inhibitory signals that would otherwise switch them off, and also by inhibiting Treg function that normally prevents T cells from responding to antigen stimulation. The antibody, therefore, removes two brakes that prevent the immune system from responding to and killing cancer cells. In contrast, some other antagonist LAG-3 antibodies in development target only the effector T cell pathway and don’t address the Treg pathway.

LAG525, a humanised form of IMP701, is being evaluated in several Phase I and/or Phase II clinical trials in combination with Novartis’ PD1 inhibitor spartalizumab for the treatment of various cancers. Novartis has full responsibility for the continued development of the antibody program and Immutep is eligible to receive development-based milestone payments and royalties on sales following the commercialisation of the antibody.

Further information on the clinical studies may be obtained at:
https://clinicaltrials.gov/ct2/show/NCT03365791
https://clinicaltrials.gov/ct2/show/NCT03499899
https://clinicaltrials.gov/ct2/show/NCT02460224
https://clinicaltrials.gov/ct2/show/NCT03742349
https://clinicaltrials.gov/ct2/show/NCT03484923

About Immutep
Immutep is a globally active biotechnology company that is a leader in the development of LAG-3 related immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.
Immutep’s current lead product candidate is eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3 fusion protein (LAG-3Ig), which is a first-in-class antigen presenting cell (APC) activator being explored in cancer and infectious disease. Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease. Additional LAG-3 products, including antibodies for immune response modulation, are being developed by Immutep’s large pharmaceutical partners.
Further information can be found on the Company’s website www.immutep.com

Editor Details

Last Updated: 31-Aug-2021